Direct UHPLC-DAD Method to Determine Asenapine, Paroxetine and Fluvoxamine in Human Blood Serum, Urine and Cerebrospinal Fluid

作者：Kovatsi Leda; Manousi Natalia; Papadoyannis Ioannis^*

来源：Current Pharmaceutical Analysis, 2016, 12(4): 349-356.

DOI：10.2174/1573412912666151217182814

• Asenapine
• biofluids
• fluvoxamine
• paroxetine
• cerebrospinal fluid
• UHPLC

Background: Asenapine is a new antipsychotic drug used in the treatment of schizophrenia and bipolar disorder. Paroxetine and fluvoxamine are second generation antidepressant drugs.
Objective: Herein we have developed a simple and rapid UHPLC-DAD method to determine asenapine, fluvoxamine and paroxetine. The methodology was applied to the analysis of human biofluids, namely blood serum, urine and cerebrospinal fluid.
Method: The analytes of interest were separated on an Inertsil C-8, (250 x 4.0 mm) 5 mu m, analytical column, using mobile phase consisted of acetate buffer (0.2 M, pH=4.5), methanol and acetonitrile (60: 10: 30 % v/v). Isocratic elution was performed at a flow rate of 1.7 mL/min. Photodiode array detection was applied at 231 nm for asenapine, 294 nm for paroxetine and 251 nm for fluvoxamine. Sulfadimethoxine (2.5 ng/mu L) was chosen as the internal standard. The method was validated in terms of linearity, selectivity, accuracy, precision and stability.
Results: Limits of detection and quantitation were 0.03 ng/mu L, and 0.10 ng/mu L respectively, using the S/N=3.3 and S/N=10 criteria.
Conclusion: The developed method is consistent and can be used as a useful analytical tool to monitor the three drugs in serum, urine and cerebrospinal fluid, in patients under treatment.

• 出版日期2016